Urogenital Reconstruction

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for uro-oncology and specialty urological conditions. The company's proprietary RTGel technology platform is a sustained-release, hydrogel-based drug delivery system designed to improve the therapeutic profile of existing drugs by increasing their dwell time in the urinary tract. Their lead commercial product, Jelmyto, is the first FDA-approved non-surgical treatment for low-grade upper tract urothelial cancer. UroGen is also advancing a robust pipeline, including UGN-102 for low-grade non-muscle invasive bladder cancer, aiming to transform the standard of care from surgical intervention to chemoablation.